Bluebird Ventures, managed by Sutter Hill Ventures, is a venture capital firm that primarily focuses on creating and investing in early-stage life sciences companies dedicated to developing transformative solutions for global health challenges. The firm also invests in innovative, early-stage technology companies with high growth potential and transformative business models, including sectors like AI, FinTech, and SaaS.
50% of their portfolio is in Healthcare. Their most common stage is series-b (75% of deals). Average disclosed round size is $67.8M (across 4 rounds with reported amounts).
Portfolio
4
Fund Size
$103.5M
Top Stage
Series B
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
4 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Foresight Diagnostics | Series B | $58.8M | Apr 2023 |
 Leyden Laboratories B.V. | Series B | $140M | Jan 2022 |
| Foresight Diagnostics | Series A | $12.5M | Jun 2021 |
 Nutcracker Therapeutics, Inc. | Series B | $60M | Sep 2020 |
Top Co-Investors
Civilization Ventures2 shared
Pear VC2 shared
Foresite Capital1 shared
Agent Capital1 shared
Stanford University1 shared
ARCH Venture Partners1 shared
SoftBank Vision Fund1 shared
Casdin Capital1 shared
Invus1 shared
F-Prime Capital1 shared
Last updated: 12 April 2026